Work

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

Year: 2015

Type: erratum

Abstract: Currently, there is a phase II trial of a trivalent peptide vaccine to the gangliosides GD2, GD3, and GM2 in patients with sarcoma that have had solitary metastases excised (NCT00597272), " the corrected identifier should be NCT01141491.

Source: Sarcoma

DOI: 10.1155/2015/259817

Authors: S. P. D’Angelo, W. D. Tap, G. K. Schwartz, R. D. Carvajal

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $820

OpenAlex ID: W1524312350

Cites:

Cited by: 2

Related to: 10